Back to Archived News
AntiCancer, Inc. Receives Patent for New Type of AIDS Drug
Thursday, September 13, 2007
San Diego, CA -- AntiCancer, Inc. announced today that it has received patent 7,264,819 on September 4, 2007, entitled "Lyase treatment for P. carinii". AntiCancer is currently developing a recombinant bacterial protein drug called PEG-methioninase (methionine lyase) for cancer treatment. This drug is now in late preclinical trials for cancer. This drug is effective for cancer because cancer cells have defective methionine metabolism and cease growing when deprived of methionine. The most frequent opportunistic infection in AIDS is Pneumocystis carinii (P. carinii) which also has defective methionine metabolism and should lose its infectivity if the infected tissues are deprived of methionine by AntiCancer’s drug, PEG-methioninase. AntiCancer is currently looking for a partner to develop PEG-methioninase for the AIDS indication for patients infected with P. carinii.
AntiCancer, founded in 1984 and based in San Diego, is also developing recombinant-enzyme-based diagnostics for cancer and cardiovascular diseases as well as gene therapy of cancer and other diseases. AntiCancer has developed the leading mouse models of cancer including MetaMouse® and AngioMouse®. These models are made imageable with AntiCancer’s OncoBrite® technology using fluorescent proteins. AntiCancer also offers the Histoculture Drug Response Assay (HDRA) for individualized cancer treatment. AntiCancer pioneered hair follicle gene therapy and is now pioneering the use of pluripotent hair-follicle stem cells for regenerative medicine.
For more information, contact Charlene M. Cooper, E-mail: all@anticancer.com, Fax: (858) 268-4175.
Back to Archived News
